On October 31, the U.S. District Court for the Eastern District of Virginia granted a preliminary injunction blocking the U.S. Patent Office’s Claims and Continuations Rules from taking effect. While the rules are on hold, nutraceutical companies need to remain informed so they can make decisions that will maximize the value of their patent portfolios during these uncertain times. In her byline on www.nutraingredients-usa.com, Foley’s Courtenay Brinckerhoff highlights some of the arguments by Smithkline Beecham Corporation (GSK), who challenged the court on the rules, as well as the court’s decisions and the possible impact on nutraceutical companies
Click here for the full article.
Author(s)
Related Insights
December 24, 2025
Health Care Law Today
Gender-Affirming Care: Multi‑State Lawsuit Challenges HHS Declaration
As previously discussed in Foley’s healthcarelawtoday, on December 18, 2025, the U.S. Department of Health & Human Services (HHS) held a press conference focused on what it defined as “sex rejection procedures” (SRPs), also known as gender-affirming care (GAC) for minors, and outlined next steps.
December 23, 2025
Energy Current
FERC Opens New Paths for Co-Located Loads in PJM: What Data Center and Power Generation Developers Need to Know
Key Takeaways FERC has ordered PJM to overhaul its tariff framework for co-located generation and large loads, finding existing rules…
December 23, 2025
Foley Viewpoints
The Rush to Exit: PE Firms Pick Up the Pace in 2025
Key Points: PE firms are moving to sell portfolio companies on an accelerated timeline in 2025 after years of much longer hold…